| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 66 | 2024 | 4958 | 3.060 |
Why?
|
| Glioma | 27 | 2024 | 1978 | 1.610 |
Why?
|
| Radiosurgery | 18 | 2024 | 1383 | 1.370 |
Why?
|
| Neurosurgical Procedures | 14 | 2021 | 633 | 1.290 |
Why?
|
| Monitoring, Intraoperative | 8 | 2021 | 264 | 1.290 |
Why?
|
| Magnetic Resonance Imaging | 39 | 2024 | 7895 | 1.200 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 6 | 2020 | 339 | 1.120 |
Why?
|
| Spinal Cord Neoplasms | 6 | 2017 | 155 | 1.100 |
Why?
|
| Laser Therapy | 11 | 2020 | 466 | 1.040 |
Why?
|
| Meningeal Neoplasms | 7 | 2021 | 473 | 0.950 |
Why?
|
| Temporal Lobe | 5 | 2016 | 191 | 0.910 |
Why?
|
| Hyperthermia, Induced | 6 | 2020 | 511 | 0.760 |
Why?
|
| Meningeal Carcinomatosis | 2 | 2017 | 33 | 0.700 |
Why?
|
| Craniotomy | 10 | 2014 | 304 | 0.700 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 2 | 2017 | 106 | 0.660 |
Why?
|
| Glioblastoma | 11 | 2020 | 1776 | 0.650 |
Why?
|
| Neuronavigation | 6 | 2021 | 47 | 0.620 |
Why?
|
| Extracorporeal Shockwave Therapy | 1 | 2017 | 10 | 0.590 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2010 | 207 | 0.580 |
Why?
|
| Essential Tremor | 1 | 2017 | 91 | 0.540 |
Why?
|
| Spinal Neoplasms | 7 | 2015 | 670 | 0.490 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 2650 | 0.490 |
Why?
|
| Vision Disorders | 1 | 2017 | 242 | 0.480 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 417 | 0.480 |
Why?
|
| Neuropsychological Tests | 5 | 2016 | 1145 | 0.470 |
Why?
|
| Middle Aged | 80 | 2024 | 90352 | 0.470 |
Why?
|
| Ependymoma | 4 | 2017 | 264 | 0.460 |
Why?
|
| Humans | 137 | 2024 | 270740 | 0.460 |
Why?
|
| Immunoglobulin G | 2 | 2010 | 1129 | 0.450 |
Why?
|
| Brain Stem Neoplasms | 2 | 2011 | 100 | 0.440 |
Why?
|
| Adult | 69 | 2024 | 82040 | 0.430 |
Why?
|
| Male | 83 | 2024 | 128315 | 0.410 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 907 | 0.400 |
Why?
|
| Tinea Pedis | 1 | 2011 | 4 | 0.400 |
Why?
|
| Aged | 63 | 2024 | 73333 | 0.400 |
Why?
|
| Brain | 11 | 2021 | 4208 | 0.390 |
Why?
|
| Retrospective Studies | 46 | 2024 | 39890 | 0.380 |
Why?
|
| Radiation Injuries | 7 | 2020 | 1471 | 0.380 |
Why?
|
| Female | 81 | 2024 | 148940 | 0.370 |
Why?
|
| Incidental Findings | 2 | 2024 | 282 | 0.370 |
Why?
|
| Carcinoma | 2 | 2017 | 2610 | 0.360 |
Why?
|
| Thiophenes | 1 | 2011 | 147 | 0.360 |
Why?
|
| Off-Label Use | 1 | 2010 | 48 | 0.350 |
Why?
|
| Cerebral Ventricle Neoplasms | 2 | 2023 | 76 | 0.350 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 4481 | 0.350 |
Why?
|
| Cognition Disorders | 1 | 2015 | 762 | 0.350 |
Why?
|
| Decompression, Surgical | 2 | 2003 | 144 | 0.350 |
Why?
|
| Therapies, Investigational | 1 | 2010 | 60 | 0.350 |
Why?
|
| Melanoma | 7 | 2024 | 5595 | 0.330 |
Why?
|
| Cerebellar Neoplasms | 3 | 2008 | 477 | 0.330 |
Why?
|
| Treatment Outcome | 34 | 2024 | 33737 | 0.320 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2009 | 606 | 0.290 |
Why?
|
| Skin Diseases | 1 | 2010 | 366 | 0.280 |
Why?
|
| Herpesvirus Vaccines | 1 | 2006 | 5 | 0.280 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2006 | 8 | 0.280 |
Why?
|
| Sarcoma | 1 | 2017 | 1839 | 0.280 |
Why?
|
| Pigmentation Disorders | 1 | 2007 | 42 | 0.280 |
Why?
|
| Herpesvirus 3, Human | 1 | 2006 | 45 | 0.270 |
Why?
|
| CD11 Antigens | 1 | 2006 | 23 | 0.270 |
Why?
|
| Medication Adherence | 1 | 2011 | 513 | 0.270 |
Why?
|
| Benzoyl Peroxide | 1 | 2006 | 4 | 0.270 |
Why?
|
| Pyramidal Tracts | 3 | 2014 | 58 | 0.270 |
Why?
|
| Herpes Zoster | 1 | 2006 | 53 | 0.270 |
Why?
|
| Neuroimaging | 3 | 2019 | 401 | 0.270 |
Why?
|
| Acne Vulgaris | 1 | 2006 | 42 | 0.270 |
Why?
|
| Surgery, Computer-Assisted | 4 | 2014 | 261 | 0.260 |
Why?
|
| Dermatitis, Atopic | 1 | 2006 | 41 | 0.260 |
Why?
|
| Melanocytes | 1 | 2007 | 240 | 0.260 |
Why?
|
| Postoperative Complications | 5 | 2018 | 5681 | 0.250 |
Why?
|
| Astrocytoma | 3 | 2013 | 326 | 0.250 |
Why?
|
| Imidazoles | 1 | 2011 | 1065 | 0.250 |
Why?
|
| Onychomycosis | 1 | 2005 | 18 | 0.250 |
Why?
|
| Antifungal Agents | 1 | 2011 | 880 | 0.250 |
Why?
|
| Foot Dermatoses | 1 | 2005 | 25 | 0.250 |
Why?
|
| Speech | 2 | 2017 | 136 | 0.250 |
Why?
|
| Young Adult | 27 | 2022 | 22251 | 0.250 |
Why?
|
| Nails | 1 | 2005 | 36 | 0.250 |
Why?
|
| Brain Mapping | 7 | 2017 | 624 | 0.250 |
Why?
|
| Nicotinic Acids | 1 | 2005 | 35 | 0.250 |
Why?
|
| Ganglioneuroma | 1 | 2004 | 44 | 0.240 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 1584 | 0.240 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2004 | 38 | 0.240 |
Why?
|
| Cranial Fossa, Posterior | 2 | 2008 | 50 | 0.230 |
Why?
|
| Neurothekeoma | 1 | 2003 | 9 | 0.230 |
Why?
|
| Facial Dermatoses | 1 | 2003 | 23 | 0.230 |
Why?
|
| Hyperpigmentation | 1 | 2003 | 34 | 0.220 |
Why?
|
| Kidney Neoplasms | 5 | 2022 | 3108 | 0.220 |
Why?
|
| Thermography | 3 | 2014 | 57 | 0.220 |
Why?
|
| Psoriasis | 1 | 2005 | 143 | 0.220 |
Why?
|
| Glioma, Subependymal | 1 | 2023 | 24 | 0.220 |
Why?
|
| Forearm | 1 | 2003 | 69 | 0.220 |
Why?
|
| Combined Modality Therapy | 10 | 2023 | 9039 | 0.220 |
Why?
|
| Meningioma | 2 | 2021 | 308 | 0.220 |
Why?
|
| Tacrolimus | 1 | 2005 | 347 | 0.210 |
Why?
|
| Memory Disorders | 2 | 2015 | 287 | 0.210 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2003 | 19 | 0.210 |
Why?
|
| Wakefulness | 3 | 2014 | 156 | 0.210 |
Why?
|
| Supratentorial Neoplasms | 3 | 2013 | 77 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2023 | 10400 | 0.210 |
Why?
|
| Diagnosis, Differential | 8 | 2017 | 4831 | 0.210 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2003 | 30 | 0.210 |
Why?
|
| Encephalocele | 1 | 2003 | 59 | 0.210 |
Why?
|
| Proton Therapy | 3 | 2019 | 1637 | 0.210 |
Why?
|
| Skin Diseases, Viral | 1 | 2002 | 12 | 0.200 |
Why?
|
| Herpesvirus 2, Human | 1 | 2002 | 21 | 0.200 |
Why?
|
| Aminoquinolines | 1 | 2002 | 52 | 0.200 |
Why?
|
| Adolescent | 28 | 2022 | 32767 | 0.200 |
Why?
|
| Cerebellar Diseases | 1 | 2003 | 91 | 0.200 |
Why?
|
| Fourth Ventricle | 2 | 2023 | 49 | 0.200 |
Why?
|
| Acyclovir | 1 | 2002 | 79 | 0.200 |
Why?
|
| Pinealoma | 1 | 2022 | 50 | 0.200 |
Why?
|
| Follow-Up Studies | 13 | 2020 | 15218 | 0.190 |
Why?
|
| Language | 2 | 2017 | 326 | 0.190 |
Why?
|
| Valine | 1 | 2002 | 180 | 0.190 |
Why?
|
| Emergencies | 1 | 2003 | 224 | 0.190 |
Why?
|
| Cyclobutanes | 1 | 2021 | 36 | 0.190 |
Why?
|
| Neurosurgeons | 1 | 2021 | 17 | 0.190 |
Why?
|
| Herpes Simplex | 1 | 2002 | 100 | 0.190 |
Why?
|
| Carboxylic Acids | 1 | 2021 | 57 | 0.190 |
Why?
|
| Functional Laterality | 3 | 2017 | 274 | 0.190 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 30998 | 0.190 |
Why?
|
| Algorithms | 3 | 2020 | 3891 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2022 | 2386 | 0.180 |
Why?
|
| Surgical Equipment | 1 | 2019 | 17 | 0.170 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2014 | 293 | 0.170 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 96 | 0.170 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2019 | 585 | 0.170 |
Why?
|
| Anti-HIV Agents | 1 | 2003 | 354 | 0.170 |
Why?
|
| Benchmarking | 1 | 2021 | 275 | 0.170 |
Why?
|
| Viral Matrix Proteins | 1 | 2020 | 181 | 0.170 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 1642 | 0.160 |
Why?
|
| Mindfulness | 1 | 2020 | 56 | 0.160 |
Why?
|
| Clinical Protocols | 1 | 2021 | 477 | 0.160 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2002 | 290 | 0.160 |
Why?
|
| Survival Rate | 12 | 2019 | 12541 | 0.160 |
Why?
|
| Meditation | 1 | 2020 | 77 | 0.160 |
Why?
|
| Motor Cortex | 2 | 2010 | 126 | 0.160 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 141 | 0.160 |
Why?
|
| Skull Fractures | 1 | 1999 | 49 | 0.160 |
Why?
|
| Skull Neoplasms | 1 | 1999 | 68 | 0.160 |
Why?
|
| Dura Mater | 1 | 1999 | 85 | 0.160 |
Why?
|
| Catheter Ablation | 1 | 2023 | 575 | 0.150 |
Why?
|
| Adalimumab | 2 | 2010 | 48 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2023 | 7783 | 0.150 |
Why?
|
| Etanercept | 2 | 2010 | 68 | 0.150 |
Why?
|
| Oligodendroglioma | 2 | 2016 | 105 | 0.150 |
Why?
|
| Wernicke Area | 1 | 2017 | 11 | 0.150 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 2 | 2016 | 33 | 0.150 |
Why?
|
| Surgical Oncology | 1 | 2020 | 211 | 0.150 |
Why?
|
| Prospective Studies | 10 | 2023 | 13414 | 0.150 |
Why?
|
| Arnold-Chiari Malformation | 1 | 1998 | 53 | 0.150 |
Why?
|
| Radiotherapy Dosage | 4 | 2021 | 4019 | 0.150 |
Why?
|
| Infliximab | 2 | 2010 | 138 | 0.140 |
Why?
|
| Headache | 1 | 1998 | 175 | 0.140 |
Why?
|
| Tertiary Healthcare | 1 | 2017 | 46 | 0.140 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 675 | 0.140 |
Why?
|
| Medical Oncology | 2 | 2021 | 1465 | 0.140 |
Why?
|
| Thoracic Vertebrae | 1 | 2017 | 200 | 0.140 |
Why?
|
| Cervical Vertebrae | 1 | 2017 | 219 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2003 | 927 | 0.140 |
Why?
|
| Dacarbazine | 2 | 2016 | 502 | 0.130 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 336 | 0.130 |
Why?
|
| Body Temperature | 2 | 2014 | 161 | 0.130 |
Why?
|
| Stereotaxic Techniques | 4 | 2004 | 182 | 0.130 |
Why?
|
| Oncolytic Viruses | 1 | 2018 | 169 | 0.130 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 495 | 0.130 |
Why?
|
| Biopsy | 4 | 2018 | 3484 | 0.130 |
Why?
|
| Software | 4 | 2023 | 1355 | 0.130 |
Why?
|
| Photons | 1 | 2019 | 536 | 0.130 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 2015 | 26 | 0.130 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2021 | 1690 | 0.130 |
Why?
|
| Verbal Learning | 1 | 2015 | 84 | 0.130 |
Why?
|
| Oncolytic Virotherapy | 1 | 2018 | 239 | 0.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 880 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2017 | 293 | 0.120 |
Why?
|
| Neoplasm Grading | 5 | 2020 | 1823 | 0.120 |
Why?
|
| Preoperative Care | 3 | 2016 | 1567 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2017 | 2178 | 0.120 |
Why?
|
| Cranial Irradiation | 3 | 2006 | 322 | 0.120 |
Why?
|
| Lung Neoplasms | 5 | 2023 | 12033 | 0.120 |
Why?
|
| Electric Stimulation | 5 | 2016 | 453 | 0.120 |
Why?
|
| Patient Safety | 1 | 2019 | 613 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2020 | 3409 | 0.110 |
Why?
|
| Receptor, EphB4 | 1 | 2014 | 28 | 0.110 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2020 | 522 | 0.110 |
Why?
|
| Infrared Rays | 1 | 2014 | 62 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 1432 | 0.110 |
Why?
|
| Spinal Cord Compression | 1 | 2015 | 167 | 0.110 |
Why?
|
| Prognosis | 10 | 2023 | 22505 | 0.110 |
Why?
|
| Karnofsky Performance Status | 5 | 2015 | 174 | 0.110 |
Why?
|
| Venereal Tumors, Veterinary | 1 | 2012 | 11 | 0.110 |
Why?
|
| Phenytoin | 1 | 2013 | 81 | 0.100 |
Why?
|
| Meningitis | 2 | 2013 | 126 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 625 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 2 | 2009 | 1136 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 700 | 0.100 |
Why?
|
| Adenoviridae | 1 | 2018 | 1497 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 914 | 0.100 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 288 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1655 | 0.100 |
Why?
|
| Memory | 1 | 2015 | 445 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5574 | 0.100 |
Why?
|
| Administration, Cutaneous | 1 | 2011 | 141 | 0.100 |
Why?
|
| Catheterization | 1 | 2013 | 418 | 0.090 |
Why?
|
| Child | 14 | 2019 | 30559 | 0.090 |
Why?
|
| Pruritus | 1 | 2011 | 90 | 0.090 |
Why?
|
| Propensity Score | 1 | 2014 | 772 | 0.090 |
Why?
|
| Skin | 2 | 2007 | 1271 | 0.090 |
Why?
|
| Catheters, Indwelling | 1 | 2013 | 383 | 0.090 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2010 | 45 | 0.090 |
Why?
|
| Protons | 1 | 2003 | 481 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2015 | 6256 | 0.090 |
Why?
|
| Catheter-Related Infections | 1 | 2013 | 274 | 0.090 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 120 | 0.090 |
Why?
|
| Necrosis | 3 | 2020 | 595 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1840 | 0.090 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2010 | 32 | 0.090 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 602 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 3240 | 0.090 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2010 | 125 | 0.090 |
Why?
|
| Chemoradiotherapy | 2 | 2016 | 2027 | 0.090 |
Why?
|
| Angiomatosis | 1 | 2009 | 27 | 0.090 |
Why?
|
| Survival Analysis | 7 | 2010 | 9292 | 0.080 |
Why?
|
| Hot Temperature | 1 | 2010 | 289 | 0.080 |
Why?
|
| Anticonvulsants | 1 | 2013 | 430 | 0.080 |
Why?
|
| Tumor Burden | 3 | 2024 | 2033 | 0.080 |
Why?
|
| Brain Diseases | 2 | 2010 | 412 | 0.080 |
Why?
|
| Pyrroles | 1 | 2013 | 588 | 0.080 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 5162 | 0.080 |
Why?
|
| Positron-Emission Tomography | 3 | 2014 | 2197 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2013 | 447 | 0.080 |
Why?
|
| Tomography, Emission-Computed | 1 | 2010 | 334 | 0.080 |
Why?
|
| Cerebral Cortex | 2 | 2010 | 623 | 0.080 |
Why?
|
| Neurilemmoma | 1 | 2009 | 134 | 0.080 |
Why?
|
| Chemokine CXCL12 | 1 | 2009 | 131 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 2 | 2004 | 898 | 0.080 |
Why?
|
| Histamine H1 Antagonists | 1 | 2008 | 25 | 0.080 |
Why?
|
| Tyrphostins | 1 | 2008 | 110 | 0.080 |
Why?
|
| Infant | 8 | 2019 | 13999 | 0.080 |
Why?
|
| Pia Mater | 1 | 2008 | 17 | 0.080 |
Why?
|
| Arachnoid | 1 | 2008 | 14 | 0.080 |
Why?
|
| Disease Progression | 5 | 2019 | 6867 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2012 | 799 | 0.080 |
Why?
|
| Child, Preschool | 8 | 2019 | 17061 | 0.070 |
Why?
|
| Neoplasm Seeding | 1 | 2008 | 66 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 3707 | 0.070 |
Why?
|
| Logistic Models | 5 | 2016 | 3444 | 0.070 |
Why?
|
| Evoked Potentials, Motor | 3 | 2014 | 60 | 0.070 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2011 | 2457 | 0.070 |
Why?
|
| Topotecan | 1 | 2008 | 248 | 0.070 |
Why?
|
| Indoles | 1 | 2013 | 1028 | 0.070 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2009 | 714 | 0.070 |
Why?
|
| Patient Selection | 3 | 2020 | 2025 | 0.070 |
Why?
|
| Treatment Failure | 3 | 2024 | 1430 | 0.070 |
Why?
|
| Nanoparticles | 1 | 2012 | 585 | 0.070 |
Why?
|
| Antineoplastic Agents | 4 | 2013 | 14617 | 0.070 |
Why?
|
| Analysis of Variance | 4 | 2015 | 2315 | 0.070 |
Why?
|
| Neurologic Examination | 2 | 2009 | 262 | 0.070 |
Why?
|
| Seizures | 1 | 2013 | 1001 | 0.070 |
Why?
|
| Reproducibility of Results | 6 | 2015 | 6177 | 0.070 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2006 | 12 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2009 | 714 | 0.070 |
Why?
|
| Genomics | 1 | 2017 | 2835 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 1903 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2008 | 683 | 0.070 |
Why?
|
| Incidence | 4 | 2013 | 5824 | 0.070 |
Why?
|
| Breast Neoplasms | 4 | 2017 | 16215 | 0.070 |
Why?
|
| Germinoma | 1 | 2006 | 82 | 0.070 |
Why?
|
| Hypothalamic Neoplasms | 1 | 2006 | 13 | 0.070 |
Why?
|
| Solutions | 1 | 2006 | 108 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 4821 | 0.070 |
Why?
|
| Lasers | 2 | 2020 | 235 | 0.070 |
Why?
|
| Gels | 1 | 2006 | 106 | 0.060 |
Why?
|
| Spider Bites | 1 | 2005 | 2 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 342 | 0.060 |
Why?
|
| Spider Venoms | 1 | 2005 | 11 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2015 | 1933 | 0.060 |
Why?
|
| Hypersensitivity | 1 | 2008 | 220 | 0.060 |
Why?
|
| Clinical Trials as Topic | 3 | 2006 | 3844 | 0.060 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 2005 | 6 | 0.060 |
Why?
|
| Hydroxides | 1 | 2005 | 8 | 0.060 |
Why?
|
| Potassium Compounds | 1 | 2005 | 13 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 3530 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2002 | 4895 | 0.060 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2005 | 42 | 0.060 |
Why?
|
| Judaism | 1 | 2004 | 1 | 0.060 |
Why?
|
| Administration, Topical | 2 | 2003 | 258 | 0.060 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2005 | 112 | 0.060 |
Why?
|
| Skin Ulcer | 1 | 2005 | 74 | 0.060 |
Why?
|
| Osteosarcoma | 1 | 2002 | 950 | 0.060 |
Why?
|
| Preoperative Period | 2 | 2017 | 346 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 3917 | 0.060 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2004 | 9 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 5101 | 0.060 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2004 | 8 | 0.060 |
Why?
|
| Leg | 1 | 2006 | 213 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2008 | 509 | 0.060 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2004 | 18 | 0.060 |
Why?
|
| Religion and Medicine | 1 | 2004 | 46 | 0.060 |
Why?
|
| Age Factors | 4 | 2015 | 5457 | 0.060 |
Why?
|
| Quality of Life | 2 | 2015 | 4761 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 540 | 0.060 |
Why?
|
| Risk Factors | 7 | 2021 | 17888 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2010 | 1341 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2023 | 1060 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 5866 | 0.060 |
Why?
|
| Nervous System Diseases | 3 | 2017 | 517 | 0.060 |
Why?
|
| Fungi | 1 | 2005 | 147 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2005 | 274 | 0.060 |
Why?
|
| Back | 1 | 2003 | 49 | 0.060 |
Why?
|
| Pemphigus | 1 | 2003 | 9 | 0.060 |
Why?
|
| Fusobacterium Infections | 1 | 2003 | 30 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 4960 | 0.060 |
Why?
|
| Genome, Human | 1 | 2011 | 1888 | 0.050 |
Why?
|
| Arm | 1 | 2003 | 139 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2006 | 718 | 0.050 |
Why?
|
| Laminectomy | 1 | 2003 | 50 | 0.050 |
Why?
|
| Brain Abscess | 1 | 2003 | 74 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 2351 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2003 | 55 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2015 | 3669 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 1580 | 0.050 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 10265 | 0.050 |
Why?
|
| Models, Biological | 1 | 2011 | 3194 | 0.050 |
Why?
|
| Leukemia | 1 | 2011 | 1719 | 0.050 |
Why?
|
| Postoperative Period | 2 | 2018 | 666 | 0.050 |
Why?
|
| Immunotherapy | 2 | 2023 | 3557 | 0.050 |
Why?
|
| Angiography | 1 | 2023 | 350 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2010 | 4372 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 2271 | 0.050 |
Why?
|
| Pyridines | 1 | 2008 | 1313 | 0.050 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2004 | 327 | 0.050 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2020 | 21 | 0.050 |
Why?
|
| Cerebellum | 1 | 2004 | 470 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2005 | 1608 | 0.050 |
Why?
|
| Apyrase | 1 | 2020 | 40 | 0.040 |
Why?
|
| ROC Curve | 2 | 2014 | 1248 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2011 | 5776 | 0.040 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2004 | 442 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2001 | 247 | 0.040 |
Why?
|
| 5'-Nucleotidase | 1 | 2020 | 63 | 0.040 |
Why?
|
| Carcinoma, Papillary | 1 | 2004 | 566 | 0.040 |
Why?
|
| Cadherins | 1 | 2003 | 657 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2002 | 311 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2016 | 605 | 0.040 |
Why?
|
| Asthma | 1 | 2008 | 895 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2005 | 625 | 0.040 |
Why?
|
| Dogs | 2 | 2012 | 1160 | 0.040 |
Why?
|
| Leukapheresis | 1 | 2020 | 166 | 0.040 |
Why?
|
| Cell Line, Tumor | 4 | 2020 | 14849 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 4644 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 1312 | 0.040 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2004 | 499 | 0.040 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2004 | 551 | 0.040 |
Why?
|
| Mutation | 2 | 2024 | 15912 | 0.040 |
Why?
|
| Chondrosarcoma | 1 | 2001 | 213 | 0.040 |
Why?
|
| Cell Movement | 1 | 2007 | 2472 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2003 | 553 | 0.040 |
Why?
|
| Empathy | 1 | 2020 | 103 | 0.040 |
Why?
|
| Animals | 7 | 2020 | 61956 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 316 | 0.040 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 3035 | 0.040 |
Why?
|
| Family Health | 2 | 2011 | 349 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 2001 | 424 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 255 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 2 | 2010 | 353 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2023 | 764 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 564 | 0.040 |
Why?
|
| Medical History Taking | 1 | 1999 | 175 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 533 | 0.040 |
Why?
|
| Texas | 3 | 2020 | 6449 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 4961 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2015 | 2311 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2018 | 169 | 0.040 |
Why?
|
| Cranial Nerve Injuries | 1 | 2017 | 9 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 5923 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2003 | 1330 | 0.040 |
Why?
|
| Craniocerebral Trauma | 1 | 1999 | 154 | 0.040 |
Why?
|
| Ventriculostomy | 1 | 2017 | 43 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2015 | 4329 | 0.040 |
Why?
|
| Growth Disorders | 1 | 1999 | 223 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 400 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 496 | 0.040 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2017 | 45 | 0.030 |
Why?
|
| Consensus | 1 | 2021 | 1106 | 0.030 |
Why?
|
| Speech Disorders | 1 | 2017 | 85 | 0.030 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2017 | 89 | 0.030 |
Why?
|
| Cohort Studies | 3 | 2017 | 9470 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 1034 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2021 | 6764 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2017 | 413 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2010 | 1075 | 0.030 |
Why?
|
| Semantics | 1 | 2015 | 55 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 175 | 0.030 |
Why?
|
| Time Factors | 4 | 2017 | 13006 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 3949 | 0.030 |
Why?
|
| Machine Learning | 1 | 2019 | 360 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2016 | 2353 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2020 | 1418 | 0.030 |
Why?
|
| Neoplasm Staging | 4 | 2014 | 14012 | 0.030 |
Why?
|
| Radiography | 2 | 2015 | 1986 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 514 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2017 | 209 | 0.030 |
Why?
|
| Recurrence | 1 | 2003 | 4878 | 0.030 |
Why?
|
| Research Design | 1 | 2002 | 1569 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2015 | 255 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 2067 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2016 | 274 | 0.030 |
Why?
|
| Mental Recall | 1 | 2015 | 171 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2002 | 1253 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 729 | 0.030 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2014 | 4 | 0.030 |
Why?
|
| Psychometrics | 2 | 2010 | 973 | 0.030 |
Why?
|
| Brain Stem | 1 | 2015 | 185 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2014 | 36 | 0.030 |
Why?
|
| Autoradiography | 1 | 2014 | 154 | 0.030 |
Why?
|
| Affect | 1 | 2015 | 304 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2014 | 98 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1097 | 0.030 |
Why?
|
| Breast Neoplasms, Male | 1 | 2015 | 232 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1350 | 0.030 |
Why?
|
| Fluorescence | 1 | 2014 | 198 | 0.030 |
Why?
|
| Executive Function | 1 | 2014 | 146 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 2828 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 728 | 0.030 |
Why?
|
| Decision Making | 1 | 2020 | 1252 | 0.030 |
Why?
|
| Luciferases | 1 | 2014 | 460 | 0.030 |
Why?
|
| Attention | 1 | 2014 | 282 | 0.030 |
Why?
|
| Creatine | 1 | 2002 | 60 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 905 | 0.030 |
Why?
|
| Choline | 1 | 2002 | 73 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 927 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2020 | 5694 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2011 | 54 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 2002 | 148 | 0.020 |
Why?
|
| Lod Score | 1 | 2011 | 173 | 0.020 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2011 | 63 | 0.020 |
Why?
|
| Mice | 3 | 2020 | 35600 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 1121 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2015 | 1016 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1610 | 0.020 |
Why?
|
| Cell Division | 1 | 2015 | 2657 | 0.020 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 18 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2002 | 310 | 0.020 |
Why?
|
| Learning | 1 | 2014 | 431 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2024 | 5002 | 0.020 |
Why?
|
| Biophysical Phenomena | 1 | 2010 | 117 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 2220 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 246 | 0.020 |
Why?
|
| Electrophysiological Phenomena | 1 | 2010 | 93 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 494 | 0.020 |
Why?
|
| Temperature | 1 | 2011 | 538 | 0.020 |
Why?
|
| Corpus Callosum | 1 | 2010 | 127 | 0.020 |
Why?
|
| Nerve Fibers | 1 | 2010 | 119 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2010 | 194 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2010 | 167 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2011 | 316 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2011 | 338 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2015 | 2090 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2024 | 5438 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2010 | 138 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2015 | 1038 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 7100 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2002 | 476 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 2184 | 0.020 |
Why?
|
| Anesthesia, General | 1 | 2010 | 222 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 2014 | 862 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2008 | 107 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2008 | 88 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 251 | 0.020 |
Why?
|
| Peptides | 1 | 2014 | 1504 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 2250 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2008 | 153 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2004 | 4795 | 0.020 |
Why?
|
| Pons | 1 | 2008 | 54 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2011 | 1655 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 4328 | 0.020 |
Why?
|
| Epidural Space | 1 | 2007 | 47 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 5338 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2008 | 320 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 2042 | 0.020 |
Why?
|
| fas Receptor | 1 | 2008 | 197 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2008 | 6224 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 7914 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2009 | 593 | 0.020 |
Why?
|
| Chest Pain | 1 | 2007 | 173 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 1570 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2008 | 521 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2013 | 1838 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 2493 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 442 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 10708 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2010 | 991 | 0.020 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2006 | 303 | 0.020 |
Why?
|
| Resins, Synthetic | 1 | 2004 | 3 | 0.020 |
Why?
|
| Patch Tests | 1 | 2004 | 7 | 0.020 |
Why?
|
| Neuroanatomy | 1 | 2004 | 11 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 1051 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2010 | 1184 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 1267 | 0.010 |
Why?
|
| Peptostreptococcus | 1 | 2003 | 7 | 0.010 |
Why?
|
| Bacteroides Infections | 1 | 2003 | 10 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2008 | 1179 | 0.010 |
Why?
|
| Desmoglein 1 | 1 | 2003 | 2 | 0.010 |
Why?
|
| Mupirocin | 1 | 2003 | 20 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 1260 | 0.010 |
Why?
|
| Neoplasms | 1 | 2010 | 15927 | 0.010 |
Why?
|
| SEER Program | 1 | 2007 | 1047 | 0.010 |
Why?
|
| Genotype | 1 | 2011 | 4252 | 0.010 |
Why?
|
| Immobilization | 1 | 2003 | 91 | 0.010 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2003 | 90 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2004 | 334 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2010 | 1857 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 749 | 0.010 |
Why?
|
| Sensation Disorders | 1 | 2002 | 35 | 0.010 |
Why?
|
| Allergens | 1 | 2004 | 252 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 608 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2002 | 432 | 0.010 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2003 | 163 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 2422 | 0.010 |
Why?
|
| Methods | 1 | 2001 | 223 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2003 | 404 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2008 | 3045 | 0.010 |
Why?
|
| Respiration | 1 | 2003 | 465 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 1571 | 0.010 |
Why?
|
| Particle Accelerators | 1 | 2003 | 362 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 3187 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2008 | 4942 | 0.010 |
Why?
|
| Movement | 1 | 2003 | 556 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 1197 | 0.010 |
Why?
|
| Clostridium Infections | 1 | 2003 | 262 | 0.010 |
Why?
|
| Models, Animal | 1 | 2002 | 657 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2003 | 602 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2002 | 622 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2002 | 690 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 1379 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2003 | 909 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 2345 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2004 | 2123 | 0.010 |
Why?
|
| United States | 1 | 2011 | 15861 | 0.010 |
Why?
|
| Palliative Care | 1 | 2005 | 2178 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 7655 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 16689 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2008 | 12103 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 8130 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 8699 | 0.010 |
Why?
|